The potential benefit of angiotensin II-receptor antagonism is not limited to well-tolerated blood pressure control. Angiotensin II has complex effects on the heart and kidneys. Blocking the ...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback